Ocular Therapeutix, Inc.
Nasdaq OCUL · Bedford, MA
Works in Immunology · Neurology · Ophthalmology
Ocular Therapeutix, Inc. is a clinical trial sponsor based in Bedford, MA, listed as Nasdaq OCUL. It has 4 active clinical trials with 2,949 planned participants, in Immunology, Neurology and Ophthalmology. Since 2021 it has completed 13 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq OCUL
Fundraising
Pipeline · 4 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Ocular Therapeutix, Inc
Ocular Therapeutix, Inc is lead sponsor of 4 active clinical trials on ClinicalTrials.gov, with 2,949 planned participants, in Immunology, Neurology, Ophthalmology. Since 2021 it has completed 13 trials and stopped 1 early.
Ocular Therapeutix, Inc is based in Bedford, MA and is listed as Nasdaq OCUL. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Ocular Therapeutix, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-03.
Approve Suite is not affiliated with Ocular Therapeutix, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.